Lv1
48 积分 2024-09-01 加入
Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach
24天前
已完结
Next-Generation Anti-TNFα Agents: The Example of Ozoralizumab
24天前
已完结
Structural, nonclinical, and clinical features of ozoralizumab: A novel tumour necrosis factor inhibitor
24天前
已完结
Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials
24天前
已完结
In vitro prediction of the immunogenicity of therapeutic proteins: state of the art and current challenges and perspectives
27天前
已完结
Antibodies internalization mechanisms by dendritic cells and their role in therapeutic antibody immunogenicity
27天前
已完结
Validation of a Dendritic Cell and CD4+ T Cell Restimulation Assay Contributing to the Immunogenicity Risk Evaluation of Biotherapeutics
27天前
已完结
Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo
2个月前
已完结
Preclinical Antitumor Efficacy of a Novel Anti–c-Kit Antibody–Drug Conjugate, NN3201, in c-Kit–Positive Tumors
3个月前
已完结
Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS
3个月前
已关闭
皖公网安备34019202002308
